Outcome and prognostic factors of very old patients with primary CNS lymphoma: a retrospective analysis of patients ≥80 years treated with high-dose methotrexate-based chemotherapy. Issue 12 (15th October 2022)

• Record Type: Journal Article
• Authors: Seidel, Sabine; Kowalski, Thomas; Nilius-Eliliwi, Verena; Schroers, Roland; Schlegel, Uwe
• Is Part Of: Leukemia & lymphoma. Volume 63:Issue 12(2022)
• Page Start: 2905
• Page End: 2911
• Publication Date: 2022-10-15
• Subjects: Primary CNS lymphoma -- PCNSL -- elderly patients -- high-dose methotrexate -- intracerebroventricular therapy -- octogenarians; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2022.2100371
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Although >10% of primary CNS lymphoma (PCNSL) patients are ≥80 years, data on this population are limited. We analyzed 19 consecutive octogenarians with PCNSL treated with high-dose methotrexate (HD-MTX)-based chemotherapy at our institution concerning outcome, prognostic factors and living conditions at six-month follow-up for 11 patients alive and in remission. Seven patients received intracerebroventricular (ICV) treatment additional to systemic therapy. Median follow-up was 27.3 months. Median overall survival was 16.3 months. Positive prognosticators of survival were application of ICV treatment ( p = 0.033) and female gender ( p = 0.015). All 11 patients alive and in remission at 6-month follow-up were living at home with a median Karnofsky performance score of 60 (range 50–90) and a median instrumental activities of daily living score of 3 (range 1–8). HD-MTX-based polychemotherapy including ICV treatment was feasible in this population, patients in remission needed moderate support in everyday live.